Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

is increase was tempered by the non- recurrence of severance costs incurred in the second quarter of 2007, lower expenses related to the sales and marketing of Megace(R) ES and lower bonus and stock-based compensation.

2008 Financial Guidance

Par has adjusted its previously announced guidance for full-year 2008 earnings per diluted share from continuing operations of $0.65-$0.85 to ($0.06)-$0.38 reflecting the pricing pressure on the Company's generic business experienced in the second quarter, a challenging reimbursement environment for Megace(R) ES and higher legal costs. The Company's projections are based on its results for the first six months of 2008 and the impact of recent new product launches, as well as management's estimates regarding the impact of product competition on existing products and anticipated legal costs. This EPS range excludes anticipated pre-launch spending and milestone payments in support of Strativa's business strategy and includes the estimated impact of three potential new generic product launches (i.e., sumatriptan kits, clonidine, and certain strengths of risperidone ODT) with an expected fully diluted EPS impact of $0.24-$0.39. These estimates are, of course, subject to future developments, not all of which may be anticipated at this time.

Conference Call

Par has scheduled a conference call for Friday, August 8 at 9:00 am ET to discuss results for the second quarter of 2008. Par invites investors and the general public to listen to a webcast of the conference call. Access to the live webcast can be made via the Company's website at http://www.parpharm.com. The dial-in numbers for the conference call will be 888-713-4213 for domestic callers and 617-213-4865 for international callers. The passcode is 56885024. A replay of the conference call will be available for two weeks approximately one hour after the call. The dial-in numbers for the replay are 888-2
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... ... is excited to announce its latest product offering, PrescriberPRO Mobile. ,PrescriberPRO Mobile ... Solutions’ full database of over 1,000,000 medical prescribers. The application will provide names, ... the United States. , ...
... Lectures ... will be presented at the upcoming ICAD & 3rd ECAA Asia conference. Dr. W. ... Yu will present his latest clinical data showing successful reduction of acne using TriPollar. ... (PRWEB) January 20, 2010 ...
... strengthen host defences could be used to treat inflammatory bowel ... treatment for IBD to date, as explained in a review ... Medical Microbiology . IBD is inflammation of the gastro-intestinal ... pain. It is an emerging disease that affects 20 out ...
Cached Biology Technology:Healthcare Data Solutions Announces New Mobile Application, PrescriberPRO Mobile 2Healthcare Data Solutions Announces New Mobile Application, PrescriberPRO Mobile 3TriPollar Technology Clinically Proven to Significantly Reduce Stretch Marks and Acne 2TriPollar Technology Clinically Proven to Significantly Reduce Stretch Marks and Acne 3Promising probiotic treatment for inflammatory bowel disease 2
(Date:4/17/2014)... April 17 In the most densely forested and ... reflect two centuries of human needs, values and practices. ... clearing forests for agriculture and development, have set the ... U.S. Forest Service study reports. , The report ... and management needs in the Northern United States ...
(Date:4/17/2014)... Double-stapled peptide inhibits RSV infection , Respiratory ... lower respiratory tract infections, generating life-threating illness in ... preventive therapies are limited. RSV enters host cells ... a six-helix fusogenic bundle. Small interfering peptides that ... however, these peptides are highly susceptible to degradation. ...
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... -- A visiting researcher from Sweden in the Indiana University ... international team in culturing, characterizing and formally naming a new ... DNA sequencing from environmental samples. ,Structures on Roots ... known as Soil Clone Group 1 (SCG1), has now been ...
... park tucked away near the southern tip of Mexico,s Baja ... reserve in the world, according to a new study led ... Diego. Results of a 10-year analysis of Cabo ... of Science (PLoS) ONE journal, revealed that the total ...
... some women who naturally produce excess aromatase in their ... Results of a new animal study suggests that may ... Cancer Center, a part of Georgetown University Medical Center. ... Cancer Research, the investigators say their mice study ...
Cached Biology News:Visiting researcher at IU leads international team in formal identification of new fungi class 2Visiting researcher at IU leads international team in formal identification of new fungi class 3Hidden Baja undersea park is the world's most robust marine reserve 2Hidden Baja undersea park is the world's most robust marine reserve 3Higher estrogen production in the breast could confer greater cancer risk than thought 2Higher estrogen production in the breast could confer greater cancer risk than thought 3
Immunochemistry 1 & 2...
...
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Biology Products: